1. Home
  2. DEA vs ABCL Comparison

DEA vs ABCL Comparison

Compare DEA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Easterly Government Properties Inc.

DEA

Easterly Government Properties Inc.

HOLD

Current Price

$23.36

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$3.58

Market Cap

910.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEA
ABCL
Founded
2011
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
910.0M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
DEA
ABCL
Price
$23.36
$3.58
Analyst Decision
Buy
Buy
Analyst Count
6
5
Target Price
$24.99
$7.75
AVG Volume (30 Days)
411.6K
3.7M
Earning Date
05-26-2026
05-26-2026
Dividend Yield
7.64%
N/A
EPS Growth
50.00
10.91
EPS
0.27
N/A
Revenue
$336,099,000.00
$75,128,000.00
Revenue This Year
$9.62
N/A
Revenue Next Year
$7.17
$6.30
P/E Ratio
$87.19
N/A
Revenue Growth
11.27
160.56
52 Week Low
$7.79
$1.89
52 Week High
$24.94
$6.52

Technical Indicators

Market Signals
Indicator
DEA
ABCL
Relative Strength Index (RSI) 48.22 54.33
Support Level $22.00 $3.37
Resistance Level $23.65 $3.84
Average True Range (ATR) 0.58 0.21
MACD -0.13 0.07
Stochastic Oscillator 8.73 96.27

Price Performance

Historical Comparison
DEA
ABCL

About DEA Easterly Government Properties Inc.

Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: